Inflammation in Patients with Schizophrenia: The Therapeutic Benefits of Risperidone Plus Add-On Dextromethorphan
- 23 June 2012
- journal article
- research article
- Published by Springer Nature in Journal of Neuroimmune Pharmacology
- Vol. 7 (3) , 656-664
Abstract
Increasing evidence suggests that inflammation contributes to the etiology and progression of schizophrenia. Molecules that initiate inflammation, such as virus- and toxin-induced cytokines, are implicated in neuronal degeneration and schizophrenia-like behavior. Using therapeutic agents with anti-inflammatory or neurotrophic effects may be beneficial for treating schizophrenia. One hundred healthy controls and 95 Han Chinese patients with schizophrenia were tested in this double-blind study. Their PANSS scores, plasma interleukin (IL)-1β, tumor necrosis factor-α (TNF-α) and brain-derived neurotrophic factor (BDNF) levels were measured before and after pharmacological treatment. Pretreatment, plasma levels of IL-1β and TNF-α were significantly higher in patients with schizophrenia than in controls, but plasma BDNF levels were significantly lower. Patients were treated with the atypical antipsychotic risperidone (Risp) only or with Risp+ dextromethorphan (DM). PANSS scores and plasma IL-1β levels significantly decreased, but plasma TNF-α and BDNF levels significantly increased after 11 weeks of Risp treatment. Patients in the Risp+ DM group showed a greater and earlier reduction of symptoms than did those in the Risp-only group. Moreover, Risp+ DM treatment attenuated Risp-induced plasma increases in TNF-α. Patients with schizophrenia had a high level of peripheral inflammation and a low level of peripheral BDNF. Long-term Risp treatment attenuated inflammation and potentiated the neurotrophic function but also produced a certain degree of toxicity. Risp+ DM was more beneficial and less toxic than Risp-only treatment. Clinical Trial Registration: Protocol Record: HR-93-50; Trial Registration number: NCT01189006; URL: http://www.clinicaltrials.govKeywords
This publication has 63 references indexed in Scilit:
- Cortical Volume, Surface Area, and Thickness in Schizophrenia and Bipolar DisorderBiological Psychiatry, 2012
- Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disordersJournal of Psychiatry and Neuroscience, 2011
- Novel CSF biomarkers for Alzheimer’s disease and mild cognitive impairmentActa Neuropathologica, 2010
- Activation of brain interleukin-1β in schizophreniaMolecular Psychiatry, 2009
- Changes in plasma levels of BDNF and NGF reveal a gender-selective vulnerability to early adversity in rhesus macaquesPsychoneuroendocrinology, 2009
- Patterns of Structural MRI Abnormalities in Deficit and Nondeficit SchizophreniaSchizophrenia Bulletin, 2007
- Brain derived neurotropic factor in first-episode psychosisSchizophrenia Research, 2007
- Systemic LPS causes chronic neuroinflammation and progressive neurodegenerationGlia, 2007
- Stage-dependent BDNF serum concentrations in Alzheimer’s diseaseJournal of Neural Transmission, 2005
- Studies on the potency of various antitussive agentsInflammation Research, 1977